Imatinib Attenuates IL-1β-Induced Astrocyte Inflammatory Responses and Is Associated with Reduced NF-κB and p38 MAPK Activation: Evidence Supporting Repurposing of Tyrosine Kinase Inhibitors for Neuroinflammatory Disorders

Astrocytes play a central role in the initiation and propagation of neuroinflammatory responses involved in neurodegenerative disorders, ischemic brain injury, and cancer therapy-related cognitive impairment. Increasing evidence suggests that tyrosine kinase inhibitors (TKIs) targeting BCR-ABL/PDGFR pathway, originally developed for chronic myeloid leukemia, may exert neuroprotective effects through modulation of inflammatory signaling pathways. However, the direct effects of Imatinib on activated astrocytes remain poorly characterized. In our study, human astrocytes were stimulated with IL-1β and treated with increasing concentrations of Imatinib. After 24 h, mRNA and protein levels of the inflammatory mediators IL-6, CCL2, CXCL10, MMP-9 were assayed by qPCR and ELISA. The activation of NF-κB and p38 MAPK signaling pathways were also evaluated by using ELISA and western blot, respectively.Cell viability was determined by MTT assay. IL-1β induced a marked inflammatory phenotype characterized by increased secretion of IL-6, CCL2, CXCL10, and MMP-9 together with activation of NF-κB and p38 MAPK pathways. Imatinib significantly attenuated these responses in a dose-dependent manner without impairing cell viability. Treatment reduced inflammatory mediator production and suppressed both NF-κB and p38 MAPK activation. These findings indicate that Imatinib directly modulates astrocyte inflammatory responses. Imatinib exerts potent anti-inflammatory effects in activated astrocytes. These anti-inflammatory effects were associated with reduced NF-κB and p38 MAPK activation. These findings support the growing evidence that BCR-ABL/PDGFR-targeting TKIs may have therapeutic value beyond hematological malignancies and could represent promising candidates for the treatment of neuroinflammatory and neurodegenerative disorders.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-10826261/v1
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Imatinib Attenuates IL-1β-Induced Astrocyte Inflammatory Responses and Is Associated with Reduced NF-κB and p38 MAPK Activation: Evidence Supporting Repurposing of Tyrosine Kinase Inhibitors for Neuroinflammatory Disorders

Alessandro Allegra, Letteria Minutoli, Manlio Fazio, Herbert Ryan Marini et al.
Research Square
Neuroinflammation and Neurodegeneration Mechanisms
preprint

Imatinib Attenuates IL-1β-Induced Astrocyte Inflammatory Responses and Is Associated with Reduced NF-κB and p38 MAPK Activation: Evidence Supporting Repurposing of Tyrosine Kinase Inhibitors for Neuroinflammatory Disorders

Alessandro Allegra, Letteria Minutoli, Manlio Fazio, Herbert Ryan Marini, Stefania Stella, Fabio Stagno, Federica Aliquò, Angela D’Ascola, Adele Bottaro
preprint en

Abstract

Astrocytes play a central role in the initiation and propagation of neuroinflammatory responses involved in neurodegenerative disorders, ischemic brain injury, and cancer therapy-related cognitive impairment. Increasing evidence suggests that tyrosine kinase inhibitors (TKIs) targeting BCR-ABL/PDGFR pathway, originally developed for chronic myeloid leukemia, may exert neuroprotective effects through modulation of inflammatory signaling pathways. However, the direct effects of Imatinib on activated astrocytes remain poorly characterized. In our study, human astrocytes were stimulated with IL-1β and treated with increasing concentrations of Imatinib. After 24 h, mRNA and protein levels of the inflammatory mediators IL-6, CCL2, CXCL10, MMP-9 were assayed by qPCR and ELISA. The activation of NF-κB and p38 MAPK signaling pathways were also evaluated by using ELISA and western blot, respectively.Cell viability was determined by MTT assay. IL-1β induced a marked inflammatory phenotype characterized by increased secretion of IL-6, CCL2, CXCL10, and MMP-9 together with activation of NF-κB and p38 MAPK pathways. Imatinib significantly attenuated these responses in a dose-dependent manner without impairing cell viability. Treatment reduced inflammatory mediator production and suppressed both NF-κB and p38 MAPK activation. These findings indicate that Imatinib directly modulates astrocyte inflammatory responses. Imatinib exerts potent anti-inflammatory effects in activated astrocytes. These anti-inflammatory effects were associated with reduced NF-κB and p38 MAPK activation. These findings support the growing evidence that BCR-ABL/PDGFR-targeting TKIs may have therapeutic value beyond hematological malignancies and could represent promising candidates for the treatment of neuroinflammatory and neurodegenerative disorders.

Research Square
University of Messina (IT), Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
Good health and well-being
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon